Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION (CELG)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/10/2018 12/11/2018 12/12/2018 12/13/2018 12/14/2018 Date
68.68(c) 69.49(c) 70.9(c) 69.74(c) 68.2(c) Last
7 545 190 7 713 288 5 686 278 5 162 868 5 231 338 Volume
-2.00% +1.18% +2.03% -1.64% -2.21% Change
More quotes
Financials (USD)
Sales 2018 15 220 M
EBIT 2018 8 451 M
Net income 2018 4 192 M
Debt 2018 13 731 M
Yield 2018 -
Sales 2019 16 877 M
EBIT 2019 9 483 M
Net income 2019 5 623 M
Debt 2019 7 400 M
Yield 2019 -
P/E ratio 2018 11,82
P/E ratio 2019 8,82
EV / Sales2018 4,04x
EV / Sales2019 3,26x
Capitalization 47 689 M
More Financials
Company
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.8%); - other (0.2%): cellular therapy products and biological materials for implants,... 
Sector
Pharmaceuticals
Calendar
01/07 | 05:20pmPresentation
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
12/10MANAGEMENT TRACKS : MiMedx, Akorn, Mallinckrodt
AQ
12/05AMGEN : New BCMA-targeted therapies could help sicker patients
AQ
12/05CELGENE CORPORATION : Announces Initial Phase 1/2 Liso-cel Data in Patients with..
AQ
12/04Weekend ASH presentations hint at future of BCMA CARs
AQ
12/04CELGENE CORPORATION : Announces Results of AUGMENT Evaluating REVLIMID In Combin..
AQ
12/04CELGENE CORPORATION : and Acceleron Pharma Announce Results of the Phase 3 MEDAL..
AQ
12/04Amgen antibody shows promise in myeloma trial, gets FDA fast track
RE
12/04CELGENE CORPORATION : Announces Initial Clinical Data from Ongoing Phase 1/2 Evo..
BU
12/03CELGENE CORPORATION : and Acceleron Pharma Announce Results of the Phase 3 BELIE..
AQ
12/03CELGENE CORPORATION : and Acceleron Pharma Announce Results of the Phase 3 MEDAL..
AQ
More news
Analyst Recommendations on CELGENE CORPORATION
More recommendations
Sector news : Pharmaceuticals - NEC
12/14FDA Approves Herceptin Biosimilar Herzuma
DJ
12/14Johnson & Johnson Closes Down 10.04% After Reuters Report -- Data Talk Update
DJ
12/14ELI LILLY AND : Lilly to Acquire Pre-Clinical Pain Program From Hydra Bioscience..
DJ
12/14THYSSENKRUPP : Incoming Thyssenkrupp CFO Will Prep Conglomerate for Split
DJ
12/14Johnson & Johnson shares nosedive on report it knew of asbestos in Baby Powde..
RE
More sector news : Pharmaceuticals - NEC
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 108 $
Spread / Average Target 58%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-34.65%47 689
JOHNSON & JOHNSON-4.81%356 703
PFIZER23.05%254 040
NOVARTIS5.61%223 295
ROCHE HOLDING LTD.1.38%216 307
MERCK AND COMPANY35.92%198 877